Last reviewed · How we verify
Fulvestrant or Tamoxifen or Aromatase Inhibitor (fulvestrant-or-tamoxifen-or-aromatase-inhibitor)
Fulvestrant or Tamoxifen or Aromatase Inhibitor (generic name: fulvestrant-or-tamoxifen-or-aromatase-inhibitor) is a Small molecule drug developed by Pfizer Inc.. It is currently FDA-approved.
Fulvestrant or Tamoxifen or Aromatase Inhibitor, marketed by Pfizer Inc., is a well-established treatment in the hormone receptor-positive breast cancer segment. The key composition patent expires in 2028, providing a strong barrier to generic competition in the near term. The primary risk lies in the competitive landscape, where multiple alternatives are available, potentially eroding market share.
At a glance
| Generic name | fulvestrant-or-tamoxifen-or-aromatase-inhibitor |
|---|---|
| Sponsor | Pfizer Inc. |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer (PHASE3)
- Phase 2 Study of Amcenestrant (SAR439859) Versus Physician's Choice in Locally Advanced or Metastatic ER-positive Breast Cancer (PHASE2)
- Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer (PHASE2)
- Two Different Schedules of Palbociclib + Second Line Endocrine Therapy in Estrogen Receptor Positive, HER2 Neg Advanced/Metastatic Breast Cancer (PHASE2)
- Palbociclib for HR Positive / HER2-negative Isolated Locoregional Recurrence of Breast Cancer (PHASE3)
- A Trial of Early Detection of Molecular Relapse With Circulating Tumour DNA Tracking and Treatment With Palbociclib Plus Fulvestrant Versus Standard Endocrine Therapy in Patients With ER Positive HER2 Negative Breast Cancer (PHASE2)
- Study of Palbociclib and Trastuzumab With Endocrine Therapy in HER2-positive Metastatic Breast Cancer (PHASE2)
- Treatment of Canadian Men and Pre/Peri/Post-menopausal Women With ER+ Advanced Breast Cancer in the Real-World Setting With Hormone Therapy ± Targeted Therapy
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Fulvestrant or Tamoxifen or Aromatase Inhibitor CI brief — competitive landscape report
- Fulvestrant or Tamoxifen or Aromatase Inhibitor updates RSS · CI watch RSS
- Pfizer Inc. portfolio CI